XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.4
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Common Stock
Additional Paid-in Capital
Retained Deficit
Total
Balance at Feb. 28, 2021 $ 131,449 $ 124,684,535 $ (124,861,827) $ (45,843)
Balance (in shares) at Feb. 28, 2021 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   84,967   84,967
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   215,926   215,926
Net loss     (316,283) (316,283)
Balance at May. 31, 2021 $ 131,449 124,985,428 (125,178,110) (61,233)
Balance (in shares) at May. 31, 2021 131,448,444      
Balance at Feb. 28, 2021 $ 131,449 124,684,535 (124,861,827) (45,843)
Balance (in shares) at Feb. 28, 2021 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Net loss       (805,777)
Balance at Nov. 30, 2021 $ 131,449 125,541,505 (125,667,604) 5,350
Balance (in shares) at Nov. 30, 2021 131,448,444      
Balance at May. 31, 2021 $ 131,449 124,985,428 (125,178,110) (61,233)
Balance (in shares) at May. 31, 2021 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   87,717   87,717
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   170,403   170,403
Net loss     (224,718) (224,718)
Balance at Aug. 31, 2021 $ 131,449 125,243,548 (125,402,828) (27,831)
Balance (in shares) at Aug. 31, 2021 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   100,017   100,017
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   197,940   197,940
Net loss     (264,776) (264,776)
Balance at Nov. 30, 2021 $ 131,449 125,541,505 (125,667,604) 5,350
Balance (in shares) at Nov. 30, 2021 131,448,444      
Balance at Feb. 28, 2022 $ 131,449 125,708,240 (125,838,483) 1,206
Balance (in shares) at Feb. 28, 2022 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   40,517   40,517
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   151,334   151,334
Net loss     (231,737) (231,737)
Balance at May. 31, 2022 $ 131,449 125,900,091 (126,070,220) (38,680)
Balance (in shares) at May. 31, 2022 131,448,444      
Balance at Feb. 28, 2022 $ 131,449 125,708,240 (125,838,483) 1,206
Balance (in shares) at Feb. 28, 2022 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Net loss       (700,294)
Balance at Nov. 30, 2022 $ 131,449 126,380,700 (126,538,777) (26,628)
Balance (in shares) at Nov. 30, 2022 131,448,444      
Balance at May. 31, 2022 $ 131,449 125,900,091 (126,070,220) (38,680)
Balance (in shares) at May. 31, 2022 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   86,017   86,017
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   154,943   154,943
Net loss     (215,918) (215,918)
Balance at Aug. 31, 2022 $ 131,449 126,141,051 (126,286,138) (13,638)
Balance (in shares) at Aug. 31, 2022 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   48,017   48,017
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   191,632   191,632
Net loss     (252,639) (252,639)
Balance at Nov. 30, 2022 $ 131,449 $ 126,380,700 $ (126,538,777) $ (26,628)
Balance (in shares) at Nov. 30, 2022 131,448,444